Vitrolife AB Interim report Q3, 2024: Improved growth with solid margins


Werte in diesem Artikel
Aktien

8.26 EUR -0.08 EUR -1.02 %

GOTHENBURG, Sweden, Oct. 24, 2024 /PRNewswire/ -- 

Third quarter 

  • Sales of SEK 867 (848) million, an increase of 7% in local currencies and 2% in SEK.
  • Sales per region, in local currencies was +9% in EMEA, +2% in Americas and +9% in APAC.
  • Sales per business area, in local currencies was +13% in Consumables, +11% in Technologies and 0% in Genetics.
  • Gross margin increased to 58.6% (55.7).
  • Operating income before depreciation and amortisation (EBITDA) was SEK 289 (287) million, giving an EBITDA margin of 33.4% (33.9).
  • Operating cash flow decreased to SEK 206 million (214).
  • Net income was SEK 116 (122) million, resulting in earnings per share of SEK 0.85 (0.90).  

First nine months

  • Sales of SEK 2,650 (2,607) million, an increase of 4% in local currencies and 2% in SEK.
  • Sales per region, in local currencies was +6% in EMEA, -2% in Americas and +7% in APAC.
  • Sales per business area, in local currencies was +10% in Consumables, +20% in Technologies and -7% in Genetics.
  • Gross margin increased to 58.6% (56.1).
  • Operating income before depreciation and amortisation (EBITDA) increased to SEK 888 (842) million, giving an EBITDA margin of 33.5% (32.3).
  • Operating cash flow increased to SEK 640 million (586).
  • Net income was SEK 375 (328) million, resulting in earnings per share of SEK 2.76 (2.42).
                 

Gothenburg, October 24, 2024
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO

The information was submitted for publication, through the agency of the contact persons set out above, at 24-10-2024 08:00 CET.

Contact: 
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/interim-report-q3--2024--improved-growth-with-solid-margins,c4055545

The following files are available for download:

https://mb.cision.com/Main/1031/4055545/3070927.pdf

Interim report Q3, 2024

 

Cision View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-interim-report-q3-2024-improved-growth-with-solid-margins-302285557.html

SOURCE Vitrolife AB

Aktuelle Vitrolife Registered Aktie News

Werbung

Vitrolife Registered Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Vitrolife Registered nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"

Keine Analysen gefunden.

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.